Zydus Cadila has launched ‘Tenglyn’ -- Teneligliptin 20 mg tablets, which belongs to a new class of oral anti-diabetic agents, Gliptins. Tenglyn tablet is one of the most affordable tablets for diabetic patients and is being priced at just Rs. 7 per tablet which is almost 1/6th the price at which the Gliptins were initially launched in India.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
